Geron Corp. (NASDAQ:GERN)’s share price shot up 4.2% on Wednesday . The stock traded as high as $2.75 and last traded at $2.75, with a volume of 1,494,136 shares changing hands. The stock had previously closed at $2.64.

Several research firms recently weighed in on GERN. Zacks Investment Research downgraded Geron Corp. from a “buy” rating to a “hold” rating in a research report on Monday, April 25th. FBR & Co reiterated a “buy” rating on shares of Geron Corp. in a research report on Sunday, May 8th. Two equities research analysts have rated the stock with a sell rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $6.13.

The firm has a market cap of $437.14 million and a price-to-earnings ratio of 916.67. The company’s 50-day moving average is $2.69 and its 200 day moving average is $2.87.

Geron Corp. (NASDAQ:GERN) last announced its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, hitting the consensus estimate of ($0.06). The company had revenue of $0.74 million for the quarter, compared to analyst estimates of $0.26 million. Geron Corp.’s revenue for the quarter was up 37.0% on a year-over-year basis. During the same period in the prior year, the business posted ($0.06) earnings per share. Analysts predict that Geron Corp. will post ($0.26) EPS for the current fiscal year.

Other large investors have recently bought and sold shares of the company. Morgan Stanley raised its stake in Geron Corp. by 194.2% in the fourth quarter. Morgan Stanley now owns 268,626 shares of the biopharmaceutical company’s stock valued at $1,300,000 after buying an additional 177,313 shares during the last quarter. California State Teachers Retirement System raised its position in shares of Geron Corp. by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 292,950 shares of the biopharmaceutical company’s stock worth $1,418,000 after buying an additional 5,223 shares in the last quarter. Finally, Russell Frank Co bought a new position in shares of Geron Corp. during the fourth quarter worth $1,099,000.

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company operates through the segment, which includes discovery and development of therapeutic products for oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.